Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
★★★★★
☆☆☆☆☆
USD 200 /hr
Hire Dr. Olga L.
United States
USD 200 /hr

PhD Chemist | AI Evaluation & Validation for Life Sciences | AlphaFold, Drug Discovery, Evidence Synthesis

Profile Summary
Subject Matter Expertise
Services
Research Meta-Research, Feasibility Study
Consulting Digital Strategy Consulting, Healthcare Consulting
Data & AI Predictive Modeling, Statistical Analysis
Work Experience

New York University

- Present

Assistant Professor of Chemistry and Principal Investigator

Yeshiva University

January 2025 - Present

Founder and Principal Scientist, AI Evaluation and Evidence Lead

Health AI

November 2019 - Present

Life Sciences Consultant, Scientific Communications Liaison

GeneCentrix

November 2018 - March 2020

NIH NRSA Postdoctoral Fellow

NYU Langone Health

September 2016 - November 2019

Education

PhD, Chemistry

New York University

September 2011 - January 2017

Certifications
  • Certification details not provided.
Publications
JOURNAL ARTICLE
(2012). 6-Bromoindigo dye . ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY.
(2012). Towards the development of new anticancer drugs: The Bergman cyclization of an 11-membered ring-constrained enediynes. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY.
(2009). ORGN 371-Theoretical studies of the Bergman cyclizations of a new class of "enediynes" that incorporate a nonbenzenoid aromatic ring in place of the olefin site. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY.
REPORT
Olga Lavinda, Lawrence Meche (2026). Why AI Governance Is a Revenue Strategy, Not a Compliance Cost . Health AI.
Olga Lavinda, Lawrence Meche (2026). Why AI Governance Is a Revenue Strategy, Not a Compliance Cost . Health AI.